Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Arun, Sanyal"'
Autor:
Annieke C.G. van Baar, Ulrich Beuers, Kari Wong, Rehan Haidry, Guido Costamagna, Alia Hadefi, Jacques Deviere, Soumitra S. Ghosh, Juan Carlos Lopez-Talavera, Leonardo Rodriguez, Manoel P. Galvao Neto, Arun Sanyal, Jacques J.G.H.M. Bergman
Publikováno v:
JHEP Reports, Vol 6, Iss 6, Pp 101041- (2024)
Externí odkaz:
https://doaj.org/article/53dd3cc5411d4749bfcc56b501553ea3
Autor:
James Twiss, Diane Whalley, Lynda Doward, Maria-Magdalena Balp, Clifford A. Brass, Donna Cryer, Arun Sanyal, Quentin M. Anstee
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-14 (2023)
Abstract Background Standardized measures for evaluating patients’ experiences with nonalcoholic steatohepatitis (NASH) and their perceived changes with treatment in clinical trials have been limited. To meet this need, a patient-reported outcome (
Externí odkaz:
https://doaj.org/article/8b44ccc2a203433ba698e8da08c32158
Autor:
Yip Han Chin, Cheng Han Ng, Nicholas WS Chew, Gwyneth Kong, Wen Hui Lim, Darren Jun Hao Tan, Kai En Chan, Ansel Tang, Daniel Q Huang, Mark Y Chan, Gemma Figtree, Jiong-Wei Wang, Asim Shabbir, Chin Meng Khoo, Vincent Wai-Sun Wong, Dan Yock Young, Mohammad Shadab Siddiqui, Mazen Noureddin, Arun Sanyal, David E. Cummings, Nicholas Syn, Mark Dhinesh Muthiah
Publikováno v:
EClinicalMedicine, Vol 54, Iss , Pp 101685- (2022)
Summary: Background: There is a growing number of trials examining the effectiveness of pharmacotherapies for obesity, however, little is known about placebo and nocebo effect in these trials. Hence, we sought to examine the effect of placebo in obes
Externí odkaz:
https://doaj.org/article/222cbfecf9a94fc1ac2610b7ce7335d8
Autor:
Cheng Han Ng, Jieling Xiao, Nicholas W. S. Chew, Yip Han Chin, Kai En Chan, Jingxuan Quek, Wen Hui Lim, Darren Jun Hao Tan, Ryan Wai Keong Loke, Caitlyn Tan, Ansel Shao Pin Tang, Xin Lei Goh, Benjamin Nah, Nicholas Syn, Dan Yock Young, Nobuharu Tamaki, Daniel Q. Huang, Mohammad Shadab Siddiqui, Mazen Noureddin, Arun Sanyal, Mark Muthiah
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Background and aimsThe global prevalence of non-alcoholic fatty liver disease (NAFLD) is expected to rise continuously. Furthermore, emerging evidence has also shown the potential for concomitant depression in NAFLD. This study aims to examine the pr
Externí odkaz:
https://doaj.org/article/8eea24be9617447baaec8753cb81ac46
Autor:
Annieke C.G. van Baar, Ulrich Beuers, Kari Wong, Rehan Haidry, Guido Costamagna, Alia Hafedi, Jacques Deviere, Soumitra S. Ghosh, Juan Carlos Lopez-Talavera, Leonardo Rodriguez, Manoel P. Galvao Neto, Arun Sanyal, Jacques J.G.H.M. Bergman
Publikováno v:
JHEP Reports, Vol 1, Iss 6, Pp 429-437 (2019)
Background & Aims: Insulin resistance is a core pathophysiological defect underscoring type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). Both conditions improve with duodenal exclusion surgery. Duodenal mucosal resurfacin
Externí odkaz:
https://doaj.org/article/a3cea8a588914834a225aaab4b1d2246
Publikováno v:
Clinics in Liver Disease. 27:187-210
Autor:
Andrea Dennis, Matt D. Kelly, Carolina Fernandes, Sofia Mouchti, Jonathan A. Fallowfield, Gideon Hirschfield, Michael Pavlides, Stephen Harrison, Manu V. Chakravarthy, Rajarshi Banerjee, Arun Sanyal
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2021)
IntroductionLate stage clinical trials in non-alcoholic steatohepatitis (NASH) are currently required by the FDA to use liver biopsy as a primary endpoint. The well-reported limitations with biopsy, such as associated risks and sampling error, couple
Externí odkaz:
https://doaj.org/article/eda938ad91a242e88cb0876c4d85c0fb
Autor:
Lorraine McSweeney, Matthew Breckons, Gulnar Fattakhova, Yemi Oluboyede, Luke Vale, Laura Ternent, Maria-Magdalena Balp, Lynda Doward, Clifford A. Brass, Fiona Beyer, Arun Sanyal, Quentin M. Anstee
Publikováno v:
JHEP Reports, Vol 2, Iss 3, Pp - (2020)
Background & Aims: Non-alcoholic steatohepatitis (NASH) is known to have a negative impact on patients' health-related quality of life (HRQoL), even before progression to cirrhosis has occurred. The burden of NASH-related cirrhosis from the patient p
Externí odkaz:
https://doaj.org/article/a4e5f867d53c45769edef6f8035eda17
Autor:
Cheng Han Ng, Margaret LP Teng, Nicholas WS Chew, Kai En Chan, Jie Ning Yong, Jingxuan Quek, Darren Jun Hao Tan, Wen Hui Lim, Gabriel Sheng Jie Lee, Jessica Wong, Apichat Kaewdech, Daniel Q Huang, Jiongwei Wang, Mark Y Chan, Mazen Noureddin, Mohammad Shadab Siddiqui, Arun Sanyal, Mark Muthiah
Publikováno v:
Expert Review of Gastroenterology & Hepatology. 16:895-901
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. NAFLD is associated with dyslipidemia, and cardiovascular mortality remains the leading cause of death. While statins are the first-line therapy in hyperlipidemia, the
Autor:
Spencer Lourens, PhD, Dharma B. Sunjaya, MD, Ashwani Singal, MD, Suthat Liangpunsakul, MD, MPH, Puneet Puri, MD, Arun Sanyal, MD, Xiaowei Ren, MS, Gregory J. Gores, MD, Svetlana Radaeva, PhD, Naga Chalasani, MD, David W. Crabb, MD, Barry Katz, PhD, Patrick S. Kamath, MD, Vijay H. Shah, MD, David Crabb, MD, Suthat Liangpunsakul, MD, Andy Borst, BS, Ryan Cook, MPH, Andy Qigui Yu, PhD, David Nelson, PhD, Romil Saxena, MD, Sherrie Cummings, RN, Megan Comerford, BS, Lakye Edwards, BS, Gregory Gores, MD, Vikas Verma, PhD, Sarah Wilder, RN, BSN, Amy Olofson, RN, Amanda Schimek, Susan Walker, RN, MSN, Andras Orosz, PhD
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 1, Iss 1, Pp 37-48 (2017)
Objective: To examine the natural history of acute alcoholic hepatitis (AH) and identify predictors of mortality for AH using data from a prospective multicenter observational study. Participants and Methods: We analyzed data from 164 patients with A
Externí odkaz:
https://doaj.org/article/5e1a75153a4e49429bcb0c1b9f760fd1